Integrated Theranostic Radiopharmaceuticals: The Primary Development Direction for Radiopharmaceuticals’ Future

III. Approved Therapeutic Radiopharmaceuticals and Market Performance in China 3.1 Product Structure of Approved Radiopharmaceuticals in China As of August 2024, a total of 106 radiopharmaceutical products have been approved for marketing in China, with domestically produced products accounting for a high 98.39%—largely attributable to the short half-lives of radionuclides and their limited distribution radius. As shown in the chart above, among all approved radiopharmaceuticals in China, 26 are therapeutic agents, representing approximately 24.53% of the total; nine are theranostic (i.e., both diagnostic and therapeutic), accounting for about 8.49%. The distribution of approval timelines reveals that seven therapeutic radiopharmaceuticals were approved in 2016—a significant increase compared to pre-2016 approvals—likely driven by technological advances and growing clinical demand. 3.2 Market Size In 2023, hospital-level sales of radiopharmaceuticals in China reached RMB 3.186 billion, with a compound annual growth rate (CAGR) of approximately 20.94% over the past six years. As indicated in the chart above: diagnostic radiopharmaceuticals accounted for RMB 2.111 billion (66.26%); therapeutic radiopharmaceuticals totaled RMB 0.619 billion (19.4%), with six products commercially available, averaging RMB 103 million per product; theranostic radiopharmaceuticals amounted to RMB 0.456 billion (14.3%), with two products on the market, averaging RMB 228 million per product—the highest per-product revenue among all categories. Although per-product sales of therapeutic-only agents are lower than those of theranostic agents, the latter demonstrate outstanding commercial value. 3.3 Key Therapeutic and Theranostic Products Hospital-level sales data indicate that diagnostic radiopharmaceuticals dominate the market, while the top-performing therapeutic agents are listed below. 2023 Hospital-Level Sales Overview of Therapeutic Radiopharmaceuticals in China Product Name Market Size Indication Number of Marketing Enterprises Medical Insurance Coverage 5-Year CAGR Sodium Iodide [¹³¹I] Oral Solution RMB 454 million Theranostic 2 Class B 11.54% Iodine-125 ([¹²⁵I]) Sealed Seeds RMB 374 million Therapeutic 6 Class B 5.90% Strontium Chloride [⁸⁹Sr] Injection RMB 99 million Therapeutic 2 Not covered 16.10% Yttrium-90 ([⁹⁰Y]) Microsphere Injection RMB 86 million Therapeutic 1 Not covered 335.09% Radium Chloride [²²³Ra] Injection RMB 45 million Therapeutic 1 Not covered 551.17% Sodium Phosphate [³²P] Oral Solution RMB 15 million Therapeutic Not disclosed Not disclosed 31.15% The radiopharmaceutical market remains relatively small but is experiencing rapid growth. Prices are generally high—for instance, the [⁹⁰Y] microsphere injection costs RMB 365,000 per unit dose, and [⁸⁹Sr] chloride injection costs RMB 9,551.66—far exceeding prices of most other pharmaceuticals. Consequently, relatively few radiopharmaceuticals are included in the national medical insurance reimbursement list. With broader clinical adoption and increased patient awareness, rising usage volumes may facilitate future inclusion in medical insurance schemes—and the involvement of commercial health insurance could further expand patient access. IV. Competitive Landscape and Enterprises

Commercialization Plan for Targeted Radionuclide Ligand Drug R&D Project

Project Name: Targeted Radionuclide Ligand Drug R&D and Industrialization Project Executive Summary Core Project Overview This project focuses on the industrialization of targeted radionuclide ligand drugs—specifically, radiopharmaceuticals enabling integrated tumor diagnosis and therapy (theranostics). It aims to establish an integrated industrial base encompassing innovative R&D of medical targeted radiopharmaceuticals, pilot-scale manufacturing, GMP-compliant production of radioactive drugs, regional radiopharmacy distribution centers, radiation safety testing centers, and pharmacovigilance centers. Industry Opportunity Radiopharmaceuticals possess dual attributes—as pharmaceuticals and as radioactively regulated substances—and fall into two major categories: diagnostic and therapeutic agents. They represent a core direction of precision oncology, and theranostic radionuclide ligand therapy has emerged as a major technological revolution in global oncology drug development. According to publicly available data from the China Isotope and Radiation Industry Association, the domestic radiopharmaceutical market expanded from RMB 4.42 billion in 2020 to RMB 9.30 billion in 2025, and is projected to reach RMB 26 billion by 2030—with a 22.7% CAGR between 2025 and 2030. Therapeutic radiopharmaceuticals are growing significantly faster than diagnostic ones and serve as the primary engine of industry expansion. Globally, the overall radiopharmaceutical market is expected to reach approximately USD 17.5 billion in 2026. Key domestic industry pain points persist: (1) partial reliance on imported high-end medical isotopes, though domestic substitution is accelerating; (2) insufficient supply of innovative radioligand drugs, leaving numerous unmet clinical needs; (3) extremely high regulatory barriers—including GMP production licensing, radiation protection certification, and radiopharmacy network permits—creating formidable entry hurdles for new players; (4) alpha-emitting nuclide-based innovative drugs (e.g., actinium-225) remain in early-stage R&D, with scarce industrialization platforms; and (5) nuclear medicine departments nationwide continue expanding, especially in tertiary hospitals, driving rapid downstream clinical demand—but regional, just-in-time supply capacity remains markedly insufficient. At the national level, top-down policy documents—including the ‘Medium- and Long-Term Development Plan for Medical Isotopes (2021–2035)’ and the ‘Three-Year Action Plan for High-Quality Development of Nuclear Technology Applications (2024–2026)’—are continuously being issued, offering multi-dimensional support for radiopharmaceutical development across isotope supply, regulatory review reform, industrial implementation, and medical insurance access. Meanwhile, the National Medical Products Administration (NMPA) has established a dedicated review and approval system for radiopharmaceuticals, substantially streamlining registration pathways for innovative agents—ushering in a golden window of opportunity fueled by synergistic policy, clinical, and technological tailwinds. Domestically, the competitive landscape is highly concentrated among industry leaders: China Isotope & Radiation Co., Ltd. (CIR), Dongcheng Pharmaceutical Group, and Yuanda Pharmaceutical constitute the first tier. These incumbents leverage early-mover advantages—including regulatory licenses and nationwide radiopharmacy networks—to command dominant market shares. In contrast, emerging biotechs typically emphasize R&D but lack proprietary GMP production facilities, relying heavily on contract manufacturing—which constrains the commercialization pace of their innovative pipelines. This project adopts a differentiated strategy: rather than competing head-on with industry leaders in conventional technetium-labeled generic radiopharmaceuticals, it focuses on next-generation radioligand therapies (RLT), building an integrated platform spanning pilot-scale development, manufacturing, and regional radiopharmacy distribution—establishing a business model centered on ‘innovative pipeline + in-house manufacturing + regional distribution + CDMO services.’ Product and Technology Overview The project’s product portfolio comprises three main segments: Segment 1: Gallium-68 (⁶⁸Ga) Diagnostic Imaging Series (improved-new drugs), intended for PET imaging diagnosis of prostate cancer and neuroendocrine tumors; Segment 2: Lutetium-177 (¹⁷⁷Lu) Targeted Therapy Series, targeting PSMA and SSTR, covering both improved-new drugs and Class 1 novel drugs for advanced prostate cancer and neuroendocrine tumors;

ASPI: Scaling Isotope Production and Radiopharmacies Toward a $300M EBITDA Target by 2031

5 days ago

ASP Isotopes Inc. targets $300 million EBITDA by 2031 via isotope shipments, helium scale-up, and radiopharmacy acquisitions. The firm also pursues a VHH cancer-treatment pipeline within its expansion strategy.

TradingView

2026-03-31

ASP Isotopes Partners with University of Bristol, Survives Class-Action Lawsuit

2026-04-11

ASP Isotopes Inc Targets Initial Commercial Shipments for Key Isotopes by 2026-2027

2026-04-12

ASP Isotopes Revenue Surge Tests Bullish Growth Narratives Against Deepening Losses

2026-04-13

ASP Isotopes Reports Q4 Revenue Surge Amid Widening Losses

2026-04-13

$333M Cash Backs ASP Isotopes' 2026 Push for First Sales